A detailed history of Baxter Bros Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Baxter Bros Inc holds 13,950 shares of BMY stock, worth $732,375. This represents 0.09% of its overall portfolio holdings.

Number of Shares
13,950
Previous 16,204 13.91%
Holding current value
$732,375
Previous $672,000 7.29%
% of portfolio
0.09%
Previous 0.09%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$39.66 - $51.75 $89,393 - $116,644
-2,254 Reduced 13.91%
13,950 $721,000
Q2 2024

Jul 15, 2024

SELL
$40.25 - $52.99 $50,473 - $66,449
-1,254 Reduced 7.18%
16,204 $672,000
Q1 2024

Apr 26, 2024

SELL
$47.98 - $54.4 $215,814 - $244,691
-4,498 Reduced 20.49%
17,458 $946,000
Q4 2023

May 17, 2024

BUY
$48.48 - $57.85 $218,063 - $260,209
4,498 Added 25.76%
21,956 $1.13 Million
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $432,393 - $515,964
-8,919 Reduced 28.89%
21,956 $1.13 Million
Q3 2023

May 17, 2024

BUY
$57.89 - $64.73 $776,710 - $868,482
13,417 Added 76.85%
30,875 $1.79 Million
Q3 2023

Oct 23, 2023

SELL
$57.89 - $64.73 $428,559 - $479,196
-7,403 Reduced 19.34%
30,875 $1.79 Million
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $17,392 - $19,312
-273 Reduced 0.71%
38,278 $2.45 Million
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $52,108 - $59,102
-793 Reduced 2.02%
38,551 $2.67 Million
Q4 2022

Jan 31, 2023

SELL
$68.48 - $81.09 $122,921 - $145,556
-1,795 Reduced 4.36%
39,344 $2.83 Million
Q3 2022

Nov 10, 2022

SELL
$0.13 - $76.84 $8 - $5,301
-69 Reduced 0.17%
41,139 $2.93 Million
Q2 2022

Jul 25, 2022

SELL
$72.62 - $79.98 $104,863 - $115,491
-1,444 Reduced 3.39%
41,208 $3.17 Million
Q1 2022

Apr 20, 2022

SELL
$61.48 - $73.72 $105,376 - $126,356
-1,714 Reduced 3.86%
42,652 $3.12 Million
Q4 2021

Jan 14, 2022

SELL
$53.63 - $62.52 $288,153 - $335,919
-5,373 Reduced 10.8%
44,366 $2.77 Million
Q3 2021

Oct 25, 2021

SELL
$59.17 - $69.31 $73,429 - $86,013
-1,241 Reduced 2.43%
49,739 $2.94 Million
Q2 2021

Aug 11, 2021

SELL
$61.91 - $67.42 $79,863 - $86,971
-1,290 Reduced 2.47%
50,980 $3.41 Million
Q1 2021

Apr 23, 2021

BUY
$59.34 - $66.74 $237,953 - $267,627
4,010 Added 8.31%
52,270 $3.3 Million
Q4 2020

Jan 25, 2021

BUY
$57.74 - $65.43 $168,774 - $191,251
2,923 Added 6.45%
48,260 $2.99 Million
Q3 2020

Nov 05, 2020

BUY
$57.43 - $63.64 $178,492 - $197,793
3,108 Added 7.36%
45,337 $2.73 Million
Q2 2020

Jul 31, 2020

BUY
$54.82 - $64.09 $462,132 - $540,278
8,430 Added 24.94%
42,229 $2.48 Million
Q1 2020

Apr 17, 2020

BUY
$46.4 - $67.43 $688,622 - $1 Million
14,841 Added 78.28%
33,799 $1.88 Million
Q4 2019

Jan 10, 2020

BUY
$49.21 - $64.19 $524,529 - $684,201
10,659 Added 128.44%
18,958 $1.22 Million
Q4 2019

Jan 09, 2020

SELL
$49.21 - $64.19 $453,371 - $591,382
-9,213 Reduced 52.61%
8,299 $490,000
Q3 2019

Oct 21, 2019

SELL
$42.77 - $50.71 $93,880 - $111,308
-2,195 Reduced 11.14%
17,512 $888,000
Q2 2019

Jul 29, 2019

BUY
$44.62 - $49.34 $122,749 - $135,734
2,751 Added 16.22%
19,707 $894,000
Q1 2019

Apr 22, 2019

SELL
$45.12 - $53.8 $48,097 - $57,350
-1,066 Reduced 5.91%
16,956 $809,000
Q4 2018

Jan 22, 2019

SELL
$48.76 - $63.23 $63,192 - $81,946
-1,296 Reduced 6.71%
18,022 $937,000
Q3 2018

Oct 11, 2018

BUY
$55.19 - $62.25 $77,486 - $87,399
1,404 Added 7.84%
19,318 $1.2 Million
Q2 2018

Jul 17, 2018

BUY
$50.53 - $62.98 $12,581 - $15,682
249 Added 1.41%
17,914 $991,000
Q1 2018

May 16, 2018

SELL
$59.92 - $68.98 $65,912 - $75,878
-1,100 Reduced 5.86%
17,665 $1.12 Million
Q4 2017

Feb 01, 2018

BUY
$59.94 - $65.35 $163,696 - $178,470
2,731 Added 17.03%
18,765 $1.15 Million
Q3 2017

Oct 16, 2017

BUY
$55.23 - $63.74 $885,557 - $1.02 Million
16,034
16,034 $1.02 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $112B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Baxter Bros Inc Portfolio

Follow Baxter Bros Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baxter Bros Inc, based on Form 13F filings with the SEC.

News

Stay updated on Baxter Bros Inc with notifications on news.